$41.03
At close: May 18, 5:00 PM EST
$41.06
0.030.07%
After Hours: May 13, 7:35 PM EST
Apellis Pharmaceuticals Inc Earnings Estimates
APLSNASDAQ
M&A: Apellis Pharmaceuticals (APLS) was acquired by Biogen (BIIB) on Thursday, May 14, 2026 for $5.6B paid in cash
Apellis Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:APLS
Apellis Pharmaceuticals (APLS) is scheduled to report Q2 earnings on July 30, 2026. Analysts estimate EPS of $-0.32 and quarterly revenue of $209.04M.
In the most recent quarter (Q1), Apellis Pharmaceuticals reported EPS of $0.15, beating estimates of $-0.37 by 1.41%. Revenue came in at $268.30M, exceeding the estimate of $202.78M by 0.32%.
Over the last 4 quarters, Apellis Pharmaceuticals has averaged an EPS surprise of 0.65% and a revenue surprise of 0.14%.
Earnings Date
Jul 30
EPS Estimate
$-0.320
Quarterly Revenue Estimate
$209.04M
Annual Revenue
(as of Mar 31)
(as of Mar 31)
$1.11B
Apellis Pharmaceuticals Earnings History
Analyze the earnings history of Apellis Pharmaceuticals using advanced sorting and filters.
Loading calendar...
Apellis Pharmaceuticals (APLS) Earnings Per Share
The chart below shows Apellis Pharmaceuticals's reported EPS compared to analyst estimates over recent quarters.
Apellis Pharmaceuticals (APLS) Revenue
The chart below shows Apellis Pharmaceuticals's reported revenue compared to analyst estimates over recent quarters.
FAQ
When is Apellis Pharmaceuticals (NASDAQ:APLS) reporting earnings?
Apellis Pharmaceuticals (APLS) is scheduled to report earnings on July 30, 2026. The last reported earnings were for reported on May 7, 2026 for Q1.
What were the latest earnings per share (EPS) for Apellis Pharmaceuticals (NASDAQ:APLS)?
The Actual EPS was $0.15, which beat the estimate of $-0.37.
What were Apellis Pharmaceuticals’s (NASDAQ:APLS) revenues?
The Actual Revenue was $268.30M, which beat the estimate of $202.78M.
